Biotech Insider Selling: Form 4 Red Flags vs 10b5-1 Plans
Most biotech insider selling is noise. Learn the 5-question checklist that separates pre-scheduled 10b5-1 plans from the bearish patterns short sellers track.
September 3, 2026Biotech News — guide
Buy-and-Bill vs Pharmacy Benefit: How Biotech Drugs Get Paid
Two channels move a drug to the patient; the channel, not the price, decides launch margins and revenue timing. How buy-and-bill and pharmacy benefit work.
September 2, 2026Contingent Value Rights (CVRs): Biotech M&A Valuation Bridge
A CVR is a contingent right to future cash if a milestone hits, and most of them expire worthless. How to read the terms, value one, and avoid the trap.
September 2, 2026Biotech Warrants and Convertible Notes: Hidden Dilution
Warrants, pre-funded warrants, and convertible notes are dilution that hasn't hit the share count yet. Here is the math that reveals the full overhang.
September 2, 2026Biotech Proxy Statements: Read Them Like an Activist
Every investor reads the 10-K but skips the DEF 14A. Here is how to read the proxy like an activist: CEO pay vs burn, golden parachutes, governance red flags.
September 2, 2026Biotech M&A: Deal Spreads, Tender Offers, Buyout Playbook
Biotech buyouts reprice in minutes. Here's how to read the deal spread, value cash vs stock vs CVR consideration, and size a tender-offer trade for investors.
September 1, 2026FDA Expedited Programs: Fast Track vs Breakthrough vs AA
Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review: which designation actually moves a biotech stock, and which is just decoration.
August 28, 2026What Is a Clinical Hold? When FDA Freezes a Biotech Stock
A clinical hold can drop a biotech stock 20-30% in a day. Learn what a hold is, full vs partial, why the FDA issues them, and how to read the 8-K and react.
August 28, 2026Biologics vs Small Molecules: Manufacturing Is the Moat
Small molecule pills go generic the day the patent dies. Biologics keep their moat for decades. Here's the manufacturing reality behind the valuation.
August 28, 2026CRL Resubmission: Class 1 vs Class 2, Timelines, and Odds
A CRL drops your biotech 30% overnight. The resubmission playbook: Class 1 vs Class 2 review, realistic timelines, and the red flags that kill your odds.
August 28, 2026How to Read Biotech SEC Filings: 10-K, 10-Q, 8-K, and S-1
Biotech's real signal lives in SEC filings, not press releases. Read the 10-K, 10-Q, 8-K, and S-1 to find cash runway, FDA catalysts, and dilution early.
August 28, 2026Track Clinical Trials Between Readouts: Key Milestones
The money in biotech is made in the quiet months between readouts. How to track enrollment, data locks, abstracts, and interim looks to get positioned early.
August 28, 2026Biosimilars Investing: The $30B Patent Cliff
Biosimilars erode originator biologics' revenue 30-50% at a time. How the BPCIA pathway works and how to spot a patent cliff before it hits your stock.
August 27, 2026Biotech Reverse Mergers and SPACs: Backdoor IPO Playbook
Reverse mergers and SPACs look like IPOs but dilute differently. Check the cash, the ownership split, and the lock-up before you buy. Here is the setup.
August 27, 2026How to Read Between the Lines of a Biotech Earnings Call
The press release is marketing; the Q&A is where the truth lives. Seven qualitative tells from the Q2 2026 earnings cycle that preceded real stock moves.
August 27, 2026How to Spot Biotech Manufacturing Risk Before the FDA Does
Most pre-PDUFA traders read the clinical data and skip the factory. Here's how to check CMC risk, Form 483s, and inspection status before a CRL costs you 40%.
August 27, 2026How Biotechs Die: Bankruptcy Risk on the Balance Sheet
The going-concern note, the reverse split, the asset auction. Learn the runway math and four tripwires that show a biotech is heading to zero, before it does.
August 27, 2026FDA Meeting Types: Type A, B, and C Decoded
Type A, B, and C FDA meetings run on a 30/60/75-day clock. Learn what each signals about approval odds and how to read a 'positive EOP2 meeting' honestly.
August 27, 2026How to Trade Biotech PDUFA Dates: A Complete Playbook
PDUFA dates are the most predictable catalysts in biotech. This playbook covers the run-up trade, the binary event, AdCom signals, position sizing, and exit rules — with real 2026 examples and our FDA calendar.
August 25, 2026Biotech ETFs: XBI vs IBB vs ARKG Compared
Three biotech ETFs can diverge 20 points in a year. Here's how XBI, IBB, and ARKG are built, which one fits your risk, and when to skip ETFs entirely.
August 22, 2026Clinical Trial Safety: AEs, Black Box Warnings, CRLs
Efficacy gets the headlines, but safety data triggers most CRLs. How to read adverse events, SAEs, discontinuation rates, and black box warnings before you buy.
August 22, 2026Drug Pricing: List vs Net Price and Gross-to-Net Gap
The list price is not the revenue. Here's the gross-to-net waterfall step by step and why the gap between list and net decides whether a launch succeeds.
August 22, 2026Royalty Financing: Sell Future Drug Royalties, Not Shares
A biotech that needs cash can sell its future royalty stream instead of issuing shares. Here's how royalty financing works and how to invest on either side.
August 22, 2026Biotech Analyst Coverage: Read the Revision, Not the Number
Analyst price targets aren't forecasts. Learn to read the revision signal (upgrades, downgrades, consensus lag) instead of the number, which is just a snapshot.
August 22, 2026Biotech IPO Lockup Expirations: The 180-Day Selloff
Lockup expirations are scheduled selloffs hiding in plain sight. Learn to find the date, read seller quality, and trade the overhang before it hits the stock.
August 22, 2026Biotech Accounting Red Flags: 5 in the Footnotes
Biotech has no revenue, so it plays different games: capitalized R&D, fudged cash runway, dilution. Here's where to find the 5 red flags in the footnotes.
August 21, 2026How Biotech Licensing Deals Create (and Destroy) Value
The headline says 'up to $2 billion.' The 8-K says $50 million upfront. Here's how to read the anatomy of a biotech licensing deal before you celebrate.
August 21, 2026How Interest Rates Control Biotech Stocks
Biotech is the most rate-sensitive sector. A 2% rate hike can cut a pre-revenue biotech's value by 40-60% with no bad news. Here's the discount-rate math.
August 21, 2026Post-Approval Biotech: First 90 Days After FDA Approval
FDA approval is not the finish line. The first 90 days determine whether a drug becomes a commercial success or write-down. Here's what to track, week by week.
August 21, 2026How to Evaluate a Biotech IPO: 5 Questions Before You Buy
Biotech IPOs are the riskiest sector IPOs. This 5-question S-1 framework separates the 20% of winners from the 80% that trade below issue within 12 months.
August 11, 2026Bispecific Antibodies: 3 Classes Reshaping Oncology
Bispecific antibodies hit two targets simultaneously. Here are the three classes, how they differ as investments, and how to evaluate a bispecific catalyst.
August 11, 2026FDA Drug Labels: What Investors Skip (and Pay For)
An FDA label defines a drug's real market -- what it treats, who it excludes, and the risks. Most investors skip it. Here are the six sections that matter.
August 11, 2026Biotech After-Hours Trading: FDA Decisions Don't Wait for Market Open
FDA drug approvals and CRLs drop between 4:00-7:00 PM ET. Here are the 3 after-hours trading patterns, the order types to use, and why the next morning's open is where price discovery actually happens.
August 11, 2026How to Read FDA Briefing Documents: The Investor's 2-Hour Guide
FDA briefing docs drop 2 days before every AdCom, 150 pages of unfiltered regulatory opinion. Here are the 5 sections to read, the 10 to skip, and how to decode the FDA's polite-but-damning language.
August 11, 2026Biotech After-Hours: FDA Decisions Don't Wait for the Open
FDA approvals and CRLs drop after the close. Here are the 3 after-hours patterns, the order types to use, and why the next open is where price is discovered.
August 11, 2026How to Read FDA Briefing Docs: The Investor's 2-Hour Guide
FDA briefing docs drop 2 days before every AdCom, 150 pages of regulatory opinion. Here are the 5 sections to read and how to decode the FDA's damning language.
August 11, 2026Biotech Dilution: Why Your Stock Drops on Good News
Dilution is the silent killer of biotech returns. Learn the cash runway formula, the 3 signals a raise is coming, and how to position around it. Here is why.
August 10, 2026Biotech Earnings: The 5 Numbers That Move Stocks
Biotech earnings are nothing like regular earnings. Ignore the GAAP EPS. Pipeline updates, cash runway, and guidance revisions are the numbers that matter.
August 10, 2026Biotech Management: The 5-Question Framework
A great management team salvages a mediocre pipeline. A bad one destroys a great one. Here's how to separate the operators from the scientists in a suit.
August 10, 2026Biotech Stock Screener: 7 Filters That Work
Standard screeners fail for biotech. Here are 7 filters — catalyst proximity, cash runway, insider clusters — that find tradeable setups, not dead money.
August 10, 2026Biotech Takeover Targets: 8-Point M&A Screen
Biotech buyouts deliver the highest single-day returns in the sector. Five patterns preceded the last 12 deals. Here is the 8-point screen for the next target.
August 10, 2026Trading Biotech Conferences: ASCO, ESMO, AAIC
Medical conferences move biotech stocks faster than most catalysts. The calendar, abstract rhythm, and six signals that separate data worth trading from noise.
August 10, 2026How to Build a Biotech Portfolio That Survives CRLs
Most biotech investors own too many stocks or too few. Here's how to build a portfolio that survives CRLs, captures catalysts, and keeps you in the game.
August 9, 2026Biotech Options: Trade FDA Catalysts Without IV Crush
Buying calls before a PDUFA date is the fastest way to lose money on a winning trade. Here is how IV crush works in biotech binaries and which strategies work.
August 9, 2026How Biotech Short Sellers Think: The 7 Signals They Track
Professional biotech short sellers look at your stock differently. Here are the 7 red flags they track, from trial design holes to cash runway cliffs.
August 9, 2026Pre-Revenue Biotech: The 5-Question Framework
Pre-revenue biotechs have no sales, no earnings, and no P/E ratio. Here is a 5-question framework for deciding if the science is worth betting on. Here is why.
August 9, 2026CAR-T Explained: How Engineered T-Cells Became a $10B Market
Your immune system already knows how to kill cancer. CAR-T just removes the blindfold. Here's how engineered T-cells work, why they cost $400K, and which stocks to watch.
August 7, 2026Companion Diagnostics Economics: How a $200 Test Unlocks a $2B Drug
Every blockbuster oncology drug requires a diagnostic test before prescribing. The company that makes the test gets paid every time the drug is used. Here's why that's the trade nobody talks about.
August 7, 2026How Biotech Drugs Get from Lab to FDA Approval: The 8-Stage Pathway
Every biotech drug travels the same 8-stage journey from lab bench to pharmacy shelf. Know the stages, the failure rates, and how long each one takes before you invest.
August 6, 2026Neuroscience Clinical Trial Endpoints Explained: What ADAS-Cog, CDR-SB, UPDRS, and PANSS Actually Measure
Neuroscience trials speak their own language of validated scales. Here's what ADAS-Cog, CDR-SB, UPDRS, PANSS, EDSS, and ALSFRS-R actually measure and what a winning score looks like.
August 6, 2026Why CAR-T Costs $500K: The Manufacturing Wall Cell Therapy Must Break
CAR-T therapies cost $400K-$600K per patient because of a 3-6 week manufacturing chain. Allogeneic and in vivo CAR-T promise to cut costs 80%. Here is the investor guide.
August 5, 2026Liquid Biopsy Explained: How a Blood Test Is Replacing the Scalpel
Liquid biopsy detects cancer DNA in blood instead of tissue. Natera, Guardant, Exact Sciences lead a $10B market. Here is the investor guide to the technology.
August 5, 2026 · Diagnostics · $NTRAHow PET Imaging Agents Get FDA Approved: The Drug-Device Hybrid
PET imaging agents follow a unique FDA pathway as drug-device hybrids. Lantheus (LNTH) at $101.50 is the pure play. Here is the investor guide.
August 5, 2026 · Diagnostics · $LNTHRare Disease Trial Design: Controls, Endpoints, Power
Rare disease trials use natural history controls, tiny patient counts, and surrogate endpoints. Here is how to read the protocol and assess the risk profile.
August 3, 2026Checkpoint Inhibitors: How Keytruda and Opdivo Work
Keytruda generates $25B+ a year. Opdivo and Yervoy add billions more. How checkpoint inhibitors release the immune brake and why oncology trials use them.
August 1, 2026In Vivo CRISPR Explained: Editing Genes Inside the Body
Ex vivo editing made Casgevy at $2M per patient. In vivo CRISPR delivers the edit via injection. How it works and why it could transform biotech valuations.
August 1, 2026mRNA Vaccines: How the Platform Works for MRNA, BNTX
mRNA vaccines aren't just COVID shots. Learn how the platform works, why lipid nanoparticles are the real moat, and what it means for biotech investors.
August 1, 2026CAR-T Cell Therapy: Autologous vs Allogeneic
Autologous CAR-T is proven but capped by manufacturing. Allogeneic is cheaper but persistence fails after 6-12 months. Here is how to evaluate both approaches.
August 1, 2026Gene Therapy Pricing: The Math Behind $3M Cures
Gene therapies cost $2-4M per dose. The price is math: tiny patient populations, AAV manufacturing costs, and one-time dosing. Here is how to value the stock.
August 1, 2026CAR-T Investing: Autologous vs Allogeneic Explained
Autologous CAR-T is proven but manufacturing-capped. Allogeneic is the off-the-shelf promise that keeps failing on durability. How to read the difference.
August 1, 2026How Vaccines Get FDA Approved: CBER, VRBPAC, ACIP
Vaccines go through CBER not CDER, face a second commercial gate at ACIP, and measure prevention. Here is where the binary risk lives for vaccine stocks.
August 1, 2026Orphan Drug Pricing: $500K a Year for 200 Patients
A drug for 500 patients at $500K/year is a $250M drug. Orphan pricing is a formula: exclusivity, value-based pricing, PRVs, and rare-disease revenue modeling.
July 31, 2026Phase 3 Readouts: 8 Steps Before You Trade
A biotech announced positive Phase 3 results and the stock is up 15%. Here is the framework for parsing endpoints, p-values, and safety before you act.
July 31, 2026Clinical Trial Readouts: HR, CI, P-Values, KM Curves
A guide to reading clinical trial data: hazard ratios, confidence intervals, p-values, survival curves, and red flags separating real results from spin.
July 31, 2026Priority Review vs Standard Review: The FDA Clock Explained
Priority Review means a 6-month FDA clock; Standard Review means 10 months. Here is how the designation changes your catalyst timeline and trade planning.
July 29, 2026What Is a Pivotal Trial? Spotting the FDA Approval Study
Not every Phase 3 trial is pivotal. Here is how to identify a registrational study on ClinicalTrials.gov and why it changes the stock move when data reads out.
July 29, 2026Gene Therapy Vectors: AAV vs Lentivirus Explained
Gene therapy press releases mention AAV and lentiviral vectors. Learn what each means for disease targeting, manufacturing cost, and safety before you invest.
July 29, 2026ADCs Explained: How Antibody-Drug Conjugates Work
ADCs are the hottest theme in oncology with $57B in pharma acquisitions. Here is how the three-part smart bomb works and why it matters for biotech investors.
July 29, 2026How to Read ClinicalTrials.gov: Catch Missed Endpoints
ClinicalTrials.gov is the FDA registry where every registrational trial is posted. Learn which fields matter and catch companies spinning missed endpoints.
July 28, 2026What Is an sBLA/sNDA? Label Expansion Filings Explained
Supplemental filings expand an approved drug label to new uses. How sBLAs and sNDAs work, why approved more often, and why they move mega-cap stocks less.
July 28, 2026What Is a Surrogate Endpoint? Most FDA Approvals Use One
Surrogate endpoints let drugs reach the market before anyone knows if they help. Here is how to spot one, why it matters for your stock, and when it fails.
July 28, 2026Biotech Valuation: 3 Methods That Work
Biotech stocks don't have earnings, so P/E is useless. Learn the three valuation methods that work: rNPV, peak sales multiples, and comparable analysis.
July 28, 2026Phase 1 vs 2 vs 3: Clinical Trial Phases Explained
Clinical trial phases drive stock risk. Phase 1 rarely moves large caps, Phase 2 doubles micro-caps, Phase 3 is binary. Here is what to look for at each phase.
July 28, 2026Clinical Trial Endpoints: Primary, Secondary, Surrogate
The endpoint decides whether a biotech drug gets approved and whether the stock pops or drops. Here is how to read four endpoint types without getting fooled.
July 27, 2026What Is a Priority Review Voucher? The $100M Biotech Asset
A priority review voucher cuts FDA review from 10 months to 6 months and sells for $80M-$180M. Here's how to track PRV awards and trade the announcement.
July 27, 2026BLA vs NDA: FDA Application Types and What They Mean
BLA or NDA tells you about manufacturing risk, exclusivity, and CRL odds. Here is how to identify which FDA filing a biotech is making before the PDUFA date.
July 26, 2026How to Read a Biotech Press Release Without Getting Fooled
Biotech press releases spin trial data. Here is the framework to read past it: primary endpoints, p-values, confidence intervals, and the 60-second checklist.
July 26, 2026What Is Accelerated Approval? The Reversible FDA Shortcut
Accelerated approval lets the FDA approve drugs on surrogate endpoints before clinical benefit is proven. Here is how to tell if your stock approval is at risk.
July 25, 2026What Is an FDA AdCom? Panel Vote Moves Biotech Stocks
An FDA AdCom vote is the most predictable binary catalyst between a drug filing and its PDUFA date. Here is how to find AdComs, read the vote, and trade them.
July 25, 2026What Is a CRL? When the FDA Says No to Your Biotech Stock
A Complete Response Letter can drop a biotech stock 40% in a day. Here's what a CRL is, why the FDA issues them, and how to spot the risk before the date.
July 24, 2026What Is a PDUFA Date? The Date That Moves Biotech Stocks
A PDUFA date is the FDA's deadline to approve or reject a drug. Here is how to find upcoming dates, read the run-up, and avoid the most common mistake.
July 24, 2026How to Invest in Biotech: PDUFA Dates, Trials, Catalysts
Biotech stocks do not trade like tech stocks. Learn how trial phases work, track FDA catalysts, and size positions for binary risk without losing your shirt.
July 24, 2026Q3 2026 FDA Calendar: Every PDUFA Date to Track
Q3 2026 FDA PDUFA calendar with every confirmed date, ticker, drug, and indication. Track binary catalysts through September and position ahead of each PDUFA.
July 24, 2026How to Trade FDA Catalysts: Run-Up, Binary Event, Exit
A practical framework for trading biotech PDUFA dates: when to enter, how to size for binary risk, read the AdCom, and when to exit on approval, CRL, or delay.
July 24, 2026How to Read a Clinical Trial Press Release Without Getting Fooled
Biotech companies are experts at spinning trial data. Here's how to read past the headline and find the numbers that actually matter — primary endpoint, p-value, confidence intervals, and the fine print.
July 19, 2026 · Guide